keyword
MENU ▼
Read by QxMD icon Read
search

oseltamivir dose

keyword
https://www.readbyqxmd.com/read/29648602/factors-associated-with-prolonged-viral-shedding-in-patients-with-avian-influenza-a-h7n9-virus-infection
#1
Yeming Wang, Qiang Guo, Zheng Yan, Daming Zhou, Wei Zhang, Shujun Zhou, Yu-Ping Li, Jing Yuan, Timothy M Uyeki, Xinghua Shen, Wenjuan Wu, Hui Zhao, Yun-Fu Wu, Jia Shang, Zhengguang He, Yi Yang, Hongsheng Zhao, Yongqing Hong, Zehua Zhang, Min Wu, Tiemin Wei, Xilong Deng, Yijun Deng, Li-Hua Cai, Weihua Lu, Hongmei Shu, Lin Zhang, Hong Luo, Y Ing Zhou, Heng Weng, Keyi Song, Li Yao, Mingguang Jiang, Boliang Zhao, Ruibin Chi, Boqi Guo, Lin Fu, Long Yu, Haiyan Min, Pu Chen, Shuifang Chen, Liang Hong, Wei Mao, Xiaoping Huang, Lijun Gu, Hui Li, Chen Wang, Bin Cao
Background: Data are limited on the impact of neuraminidase inhibitor (NAI) treatment on avian influenza A(H7N9) virus RNA shedding. Methods: In this multicenter, retrospective study, data were collected from adults hospitalized with A(H7N9) infection during 2013-2017 in China. We compared clinical features and A(H7N9) shedding among patients with different NAI doses and combination therapies and evaluated factors associated with A(H7N9) shedding, using Cox proportional hazards regression...
April 10, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29582403/medications-and-prescribing-patterns-as-factors-associated-with-hospitalizations-from-long-term-care-facilities-a-systematic-review
#2
REVIEW
Kate N Wang, J Simon Bell, Esa Y H Chen, Julia F M Gilmartin-Thomas, Jenni Ilomäki
BACKGROUND: Residents of long-term care facilities (LTCFs) are at high risk of hospitalization. Medications are a potentially modifiable risk factor for hospitalizations. OBJECTIVE: Our objective was to systematically review the association between medications or prescribing patterns and hospitalizations from LTCFs. METHODS: We searched MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and International Pharmaceutical Abstracts (IPA) from inception to August 2017 for longitudinal studies reporting associations between medications or prescribing patterns and hospitalizations...
March 26, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29572682/the-inhibitory-effect-of-sodium-baicalin-on-oseltamivir-resistant-influenza-a-virus-via-reduction-of-neuraminidase-activity
#3
Jing Jin, Yuanjin Chen, Dechuan Wang, Lingman Ma, Min Guo, Changlin Zhou, Jie Dou
Baicalin was identified as a neuraminidase (NA) inhibitor displaying anti-influenza A virus (IAV) activity. However, its poor solubility in saline has limited its use in the clinic. We generated sodium baicalin and showed that it exhibited greatly increased solubility in saline. Its efficacy against oseltamivir-resistant mutant A/FM/1/47-H275Y (H1N1-H275Y) was evaluated in vitro and in vivo. Results showed that 10 μM of sodium baicalin inhibited A/FM/1/47 (H1N1), A/Beijing/32/92 (H3N2) and H1N1-H275Y in MDCK cells in a dose-dependent manner, with inhibitory rates of 83...
March 23, 2018: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/29522425/san-wu-huangqin-decoction-a-chinese-herbal-formula-inhibits-influenza-a-pr-8-34-h1n1-virus-infection-in-vitro-and-in-vivo
#4
Qinhai Ma, Qingtian Yu, Xuefeng Xing, Sinian Liu, Chunyu Shi, Jiabo Luo
The San Wu Huangqin Decoction (SWHD), a traditional Chinese medicine formula, is used to treat colds caused by exposure to wind-pathogen, hyperpyrexia, infectious diseases and cancer; moreover, it is used for detoxification. The individual herbs of SWHD, such as Sophora flavescens and Scutellaria baicalensis , exhibit a wide spectrum of antiviral, anti-inflammatory, antibacterial, anticancer and other properties. The Chinese compound formula of SWHD is composed of S. flavescens, S. baicalensis and Rehmannia glutinosa ...
March 9, 2018: Viruses
https://www.readbyqxmd.com/read/29487035/clinical-effectiveness-of-four-neuraminidase-inhibitors-oseltamivir-zanamivir-laninamivir-and-peramivir-for-children-with-influenza-a-and-b-in-the-2014-2015-to-2016-2017-influenza-seasons-in-japan
#5
Nobuhisa Ishiguro, Naoko Koseki, Miki Kaiho, Tadashi Ariga, Hideaki Kikuta, Koji Oba, Takehiro Togashi, Keisuke Morita, Akira Inagawa, Akiko Okamura, Shigeru Yamazaki, Satoru Shida, Mutsuko Konno, Nobuaki Kawamura, Akihito Ishizaka, Kimihiko Takada, Keiji Tsubakihara, Naoko Nagano, Mutsuo Shibata, Hideto Furuyama, Yoshihiro Matsuzono, Akemi Koike, Mari Murashita, Yoshio Hatae, Hideki Arioka, Tatsuru Yamanaka, Toru Watanabe, Yuuichi Tabata, Yoshihiro Kumita, Kyosuke Hazama, Yasushi Akutsu, Hayato Aoyagi, Chie Tobise, Katsuki Azuma, Kohichi Yasoshima, Yoko Sawada, Kazuyuki Uetsuji, Akira Tsuchida, Akira Tsuchiyama, Kazue Yasuda, Yasuhisa Odagawa, Mikio Yoshioka
The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1...
February 24, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/29446343/cost-utility-analysis-of-antiviral-use-under-pandemic-influenza-using-a-novel-approach-linking-pharmacology-epidemiology-and-heath-economics
#6
D B C Wu, N Chaiyakunapruk, C Pratoomsoot, K K C Lee, H Y Chong, R E Nelson, P F Smith, C M Kirkpatrick, M A Kamal, K Nieforth, G Dall, S Toovey, D C M Kong, A Kamauu, C R Rayner
Simulation models are used widely in pharmacology, epidemiology and health economics (HEs). However, there have been no attempts to incorporate models from these disciplines into a single integrated model. Accordingly, we explored this linkage to evaluate the epidemiological and economic impact of oseltamivir dose optimisation in supporting pandemic influenza planning in the USA. An HE decision analytic model was linked to a pharmacokinetic/pharmacodynamics (PK/PD) - dynamic transmission model simulating the impact of pandemic influenza with low virulence and low transmissibility and, high virulence and high transmissibility...
March 2018: Epidemiology and Infection
https://www.readbyqxmd.com/read/29438483/statin-use-and-risks-of-influenza-related-outcomes-among-older-adults-receiving-standard-dose-or-high-dose-influenza-vaccines-through-medicare-during-2010-2015
#7
Hector S Izurieta, Yoganand Chillarige, Jeffrey A Kelman, Richard Forshee, Yandong Qiang, Michael Wernecke, Jill M Ferdinands, Yun Lu, Yuqin Wei, Wenjie Xu, Michael Lu, Alicia Fry, Douglas Pratt, David K Shay
Background: Statins are used to reduce cardiovascular disease risk. Recent studies suggest that statin use may be associated with an increased influenza risk among influenza vaccinees. We used Medicare data to evaluate associations between statins and risks of influenza-related encounters among vaccinees. Methods: In this retrospective cohort study, we identified Medicare beneficiaries aged >65 years who received high-dose (HD) or standard-dose (SD) influenza vaccines at pharmacies from 2010-11 through 2014-15...
February 9, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29411162/ensuring-safe-drug-administration-to-pediatric-patients-with-renal-dysfunction-a-multicenter-study
#8
Ryoko Harada, Kenji Ishikura, Shunsuke Shinozuka, Naoaki Mikami, Riku Hamada, Hiroshi Hataya, Yoshihiko Morikawa, Tae Omori, Hirotaka Takahashi, Yuko Hamasaki, Tetsuji Kaneko, Kazumoto Iijima, Masataka Honda
BACKGROUND: In pediatric patients, due to variations in baseline serum creatinine (Cr) reference values, renal dysfunctions sometimes go unnoticed. In addition, renally excreted drugs need dose adjustment while nephrotoxic drugs should be avoided altogether in patients with impaired renal function. However, most physicians are apparently unaware of these facts and may administer these drugs to vulnerable patients. METHODS: We administered a questionnaire to all physicians and pharmacists specializing in pediatric medical care at six Tokyo metropolitan government-run hospitals in Japan...
February 6, 2018: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29342251/kinetics-of-serological-responses-in-critically-ill-patients-hospitalized-with-influenza-a-h1n1-pdm09-virus-infection-in-canada-2009-2011
#9
Melissa A Rolfes, F Liaini Gross, Brendan Flannery, Adrienne F A Meyers, Ma Luo, Nathalie Bastien, Robert A Fowler, Jacqueline M Katz, Min Z Levine, Anand Kumar, Timothy M Uyeki
Background: The kinetics of the antibody response during severe influenza are not well documented. Methods: Critically ill patients with influenza A(H1N1)pdm09 virus infection, confirmed by RT-PCR or seroconversion (≥4-fold rise in titers), during 2009-2011 in Canada were prospectively studied. Antibody titers in serially collected sera were determined using hemagglutinin inhibition (HAI) and microneutralization assays. Average antibody curves were estimated using linear mixed effects models and compared by patient outcome, age, and corticosteroid treatment...
January 12, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29325970/the-role-of-adjuvant-immunomodulatory-agents-for-treatment-of-severe-influenza
#10
REVIEW
David S Hui, Nelson Lee, Paul K Chan, John H Beigel
A severe inflammatory immune response with hypercytokinemia occurs in patients hospitalized with severe influenza, such as avian influenza A(H5N1), A(H7N9), and seasonal A(H1N1)pdm09 virus infections. The role of immunomodulatory therapy is unclear as there have been limited published data based on randomized controlled trials (RCTs). Passive immunotherapy such as convalescent plasma and hyperimmune globulin have some studies demonstrating benefit when administered as an adjunctive therapy for severe influenza...
February 2018: Antiviral Research
https://www.readbyqxmd.com/read/29277445/biased-g-protein-coupled-receptor-agonism-mediates-neu1-sialidase-and-matrix-metalloproteinase-9-crosstalk-to-induce-transactivation-of-insulin-receptor-signaling
#11
Fiona Haxho, Sabah Haq, Myron R Szewczuk
G protein-coupled receptors (GPCR) can participate in a number of signaling pathways, and this property led to the concept of biased GPCR agonism. Agonists, antagonists and allosteric modulators can bind to GPCRs in different ways, creating unique conformations that differentially modulate signaling through one or more G proteins. A unique neuromedin B (NMBR) GPCR-signaling platform controlling mammalian neuraminidase-1 (Neu1) and matrix metalloproteinase-9 (MMP9) crosstalk has been reported in the activation of the insulin receptor (IR) through the modification of the IR glycosylation...
March 2018: Cellular Signalling
https://www.readbyqxmd.com/read/29214495/comparison-of-anti-influenza-virus-activity-and-pharmacokinetics-of-oseltamivir-free-base-and-oseltamivir-phosphate
#12
Jin Soo Shin, Keun Bon Ku, Yejin Jang, Yi-Seul Yoon, Daeho Shin, Oh Seung Kwon, Yun Young Go, Seong Soon Kim, Myoung Ae Bae, Meehyein Kim
Influenza viruses are major human respiratory pathogens that cause high morbidity and mortality worldwide. Currently, prophylactic vaccines and therapeutic antiviral agents are used to prevent and control influenza virus infection. Oseltamivir free base (OSV-FB), a modified generic antiviral drug of Tamiflu (oseltamivir phosphate, OSV-P), was launched in the Republic of Korea last year. Here, we examine the bioequivalence of these two compounds by assessing their antiviral efficacy in infected cells and in a mouse model...
December 2017: Journal of Microbiology / the Microbiological Society of Korea
https://www.readbyqxmd.com/read/29100887/a-pharmacologically-immunosuppressed-mouse-model-for-assessing-influenza-b-virus-pathogenicity-and-oseltamivir-treatment
#13
Bindumadhav M Marathe, Heba H Mostafa, Peter Vogel, Philippe Noriel Q Pascua, Jeremy C Jones, Charles J Russell, Richard J Webby, Elena A Govorkova
Immunocompromised patients are highly susceptible to influenza virus infections. Although neuraminidase inhibitor (NAI) therapy has proved effective in these patients, the treatment regimens require optimization, which can be partly addressed via animal models. Here, we describe a pharmacologically immunosuppressed mouse model for studying the pathogenesis of influenza B viruses and evaluating the efficacy of antiviral treatment. We modeled clinical regimens for dexamethasone and cyclophosphamide to immunosuppress BALB/c mice that were then inoculated with B/Phuket/3073/2013 (Yamagata lineage) or B/Brisbane/60/2008 (BR/08, Victoria lineage) virus...
October 31, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29091888/oroxylin-a-suppresses-influenza-a-virus-replication-correlating-with-neuraminidase-inhibition-and-induction-of-ifns
#14
Jing Jin, Shuo Chen, Dechuan Wang, Yuanjin Chen, Yuxu Wang, Min Guo, Changlin Zhou, Jie Dou
Because it is highly contagious, the influenza A virus (IAV) has the potential to cause pandemics in humans. The emergence of drug-resistant strains requires the development of new chemical therapeutics. Oroxylin A (OA) is a flavonoid which has been shown to have antioxidant and antitumor effects. However, intensive studies in which OA fights against different influenza virus strains and the underlying antiviral mechanisms have not been reported. In our study, the antiviral activities in cells and in mice, the preliminary mechanisms of OA were investigated...
January 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29090056/oseltamivir-tamiflu-induced-bilateral-ciliochoroidal-effusion-and-angle-closure-glaucoma-what-type-of-idiosyncratic-reaction
#15
Shahin Yazdani, Hamed Esfandiari, Sare Safi, Alireza Fatemi
PURPOSE: To report a case of bilateral acute angle closure glaucoma after one dose of oseltamivir 75 mg. CASE REPORT: A 37-year-old man with a history of influenza developed high intraocular pressure and uniformly shallow anterior chamber in both eyes, 5 hours after the first dose of oseltamivir 75 mg. The condition was managed successfully with topical cycloplegic and systemic/topical antiglaucoma medications. CONCLUSION: Since a presumed idiosyncratic reaction developed right after the first dose of the medication, it challenges the common concept of adaptive immune system involvement in this type of reaction in medication-related ciliochoroidal effusion...
October 2017: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29066417/combined-aerosolized-toll-like-receptor-ligands-are-an-effective-therapeutic-agent-against-influenza-pneumonia-when-co-administered-with-oseltamivir
#16
Miguel M Leiva-Juarez, Carson T Kirkpatrick, Brian E Gilbert, Brenton Scott, Michael J Tuvim, Burton F Dickey, Scott E Evans, Diane Markesich
Influenza pneumonia remains a common and debilitating viral infection despite vaccination programs and antiviral agents developed for prophylaxis and treatment. The neuraminidase inhibitor oseltamivir is frequently prescribed for established influenza A virus infections, but the emergence of neuraminidase inhibitor resistant viruses, a brief therapeutic window and competing diagnoses complicate its use. PUL-042 is a clinical stage, aerosol drug comprised of synthetic ligands for Toll-like receptor (TLR) 2/6 and TLR 9...
January 5, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28958678/oseltamivir-amantadine-and-ribavirin-combination-antiviral-therapy-versus-oseltamivir-monotherapy-for-the-treatment-of-influenza-a-multicentre-double-blind-randomised-phase-2-trial
#17
RANDOMIZED CONTROLLED TRIAL
John H Beigel, Yajing Bao, Joy Beeler, Weerawat Manosuthi, Alex Slandzicki, Sadia M Dar, John Panuto, Richard L Beasley, Santiago Perez-Patrigeon, Gompol Suwanpimolkul, Marcelo H Losso, Natalie McClure, Dawn R Bozzolo, Christopher Myers, H Preston Holley, Justin Hoopes, H Clifford Lane, Michael D Hughes, Richard T Davey
BACKGROUND: Influenza continues to have a substantial socioeconomic and health impact despite a long established vaccination programme and approved antivirals. Preclinical data suggest that combining antivirals might be more effective than administering oseltamivir alone in the treatment of influenza. METHODS: We did a randomised, double-blind, multicentre phase 2 trial of a combination of oseltamivir, amantadine, and ribavirin versus oseltamivir monotherapy with matching placebo for the treatment of influenza in 50 sites, consisting of academic medical centre clinics, emergency rooms, and private physician offices in the USA, Thailand, Mexico, Argentina, and Australia...
December 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28948652/pharmacokinetic-changes-of-antibiotic-antiviral-antituberculosis-and-antifungal-agents-during-extracorporeal-membrane-oxygenation-in-critically-ill-adult-patients
#18
REVIEW
J Hahn, J H Choi, M J Chang
WHAT IS KNOWN AND OBJECTIVE: Extracorporeal membrane oxygenation (ECMO) is a life-saving system used for critically ill patients with cardiac and/or respiratory failure. The pharmacokinetics (PK) of drugs can change in patients undergoing ECMO, which can result in therapeutic failure or drug toxicity requiring further management of drug complications. In this review, we discussed changes in the PK of antibiotic, antiviral, antituberculosis and antifungal agents administered to adult patients on ECMO...
December 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28936484/cetylpyridinium-chloride-cpc-exhibits-potent-rapid-activity-against-influenza-viruses-in-vitro-and-in-vivo
#19
Daniel L Popkin, Sarah Zilka, Matthew Dimaano, Hisashi Fujioka, Cristina Rackley, Robert Salata, Alexis Griffith, Pranab K Mukherjee, Mahmoud A Ghannoum, Frank Esper
BACKGROUND: There is a continued need for strategies to prevent influenza. While cetylpyridinium chloride (CPC), a broad-spectrum antimicrobial agent, has an extensive antimicrobial spectrum, its ability to affect respiratory viruses has not been studied in detail. OBJECTIVES: Here, we evaluate the ability of CPC to disrupt influenza viruses in vitro and in vivo. METHODS: The virucidal activity of CPC was evaluated against susceptible and oseltamivir-resistant strains of influenza viruses...
2017: Pathogens & Immunity
https://www.readbyqxmd.com/read/28931216/emergence-of-oseltamivir-resistant-h7n9-influenza-viruses-in-immunosuppressed-cynomolgus-macaques
#20
Maki Kiso, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Ryuta Uraki, Mutsumi Ito, Noriko Nakajima, Shinya Yamada, Masaki Imai, Eiryo Kawakami, Yuriko Tomita, Satoshi Fukuyama, Yasushi Itoh, Kazumasa Ogasawara, Tiago J S Lopes, Tokiko Watanabe, Louise H Moncla, Hideki Hasegawa, Thomas C Friedrich, Gabriele Neumann, Yoshihiro Kawaoka
Antiviral compounds (eg, the neuraminidase inhibitor oseltamivir) are invaluable for the treatment of individuals infected with influenza A viruses of the H7N9 subtype (A[H7N9]), which have infected and killed hundreds of persons. However, oseltamivir treatment often leads to the emergence of resistant viruses in immunocompromised individuals. To better understand the emergence and properties of oseltamivir-resistant A(H7N9) viruses in immunosuppressed individuals, we infected immunosuppressed cynomolgus macaques with an A(H7N9) virus and treated them with oseltamivir...
September 1, 2017: Journal of Infectious Diseases
keyword
keyword
105012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"